Streetbeat News

Earnings

BIAF

bioAffinity Technologies (NASDAQ:BIAF) reported Q2 EPS of $(0.19), an improvement from $(0.20) YoY, and sales of $2.40M, a significant increase from $19.74K YoY.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 1:27 pm

ICAD

Icad shares are trading higher after the company reported better-than-expected Q2 revenue results.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 1:24 pm

IPWR

Ideal Power (NASDAQ:IPWR) reported Q2 EPS of $(0.31), an improvement from $(0.37) YoY, but missed sales estimates significantly with $1.33K against the expected $100.00K.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 1:23 pm

BABA

PNQI

SE

XNTK

Alibaba's Lazada achieved its first monthly profit in July 2024, driven by AI-enabled operations and improved logistics. Despite this, Lazada faces strong competition from Sea Limited's Shopee. Alibaba's international commerce retail business saw a 45% revenue increase in Q4, but its stock has declined over the past year due to domestic challenges.

Portfolio Pulse from Anusuya Lahiri

August 14, 2024 | 1:23 pm

MBRX

Moleculin Biotech shares are trading higher after the company reported better-than-expected Q2 EPS results.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 1:23 pm

DKNG

FLUT

DraftKings Inc (NASDAQ:DKNG) shares experienced increased volatility following Flutter Entertainment's (NYSE:FLUT) Q2 results, which exceeded expectations. Flutter's decision not to impose a surcharge in high-tax U.S. states initially caused DraftKings shares to drop, but they rebounded after DraftKings announced it would also not implement a surcharge. Analysts from Needham and Truist Securities reiterated Buy ratings for DraftKings with price targets of $60 and $50, respectively.

Portfolio Pulse from Adam Eckert

August 14, 2024 | 1:22 pm

VIRX

Viracta Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results and announced positive Phase 2 NAVAL-1 trial results. The company will also begin a randomized controlled trial (RCT).

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 1:22 pm

MYSZ

My Size (NASDAQ:MYSZ) reported Q2 earnings per share (EPS) of $(1.28), beating the analyst estimate of $(2.43) by 47.33%. However, sales of $1.98 million missed the $2.00 million estimate by 1.05%. Despite the sales miss, both EPS and sales showed significant improvement compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 1:20 pm

VIRX

Viracta Therapeutics Inc. (NASDAQ:VIRX) saw its stock rise after reporting positive Phase 2 NAVAL-1 trial results for its treatment of relapsed or refractory Epstein-Barr virus-positive peripheral T-cell lymphoma. The company plans to focus on this program, pausing other projects and reducing its workforce by 23%.

Portfolio Pulse from Vandana Singh

August 14, 2024 | 1:19 pm

AMIX

Autonomix Medical (NASDAQ:AMIX) reported a Q1 2025 EPS of $(0.14), which is a 100% decrease from the $(0.07) EPS loss in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 1:18 pm